| EASL recommendations on treatment of hepatitis C 2018 European Association for The Study of The Liver Journal of hepatology 69 (2), 461-511, 2018 | 1762* | 2018 |
| EASL recommendations on treatment of hepatitis C: final update of the series☆ JM Pawlotsky, F Negro, A Aghemo, M Berenguer, O Dalgard, G Dusheiko, ... Journal of hepatology 73 (5), 1170-1218, 2020 | 701 | 2020 |
| Recommendations for the management of drug–drug interactions between the COVID‐19 antiviral nirmatrelvir/ritonavir (Paxlovid) and comedications C Marzolini, DR Kuritzkes, F Marra, A Boyle, S Gibbons, C Flexner, ... Clinical Pharmacology & Therapeutics 112 (6), 1191-1200, 2022 | 167 | 2022 |
| Drug–drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort C Höner zu Siederdissen, B Maasoumy, F Marra, K Deterding, K Port, ... Clinical Infectious Diseases 62 (5), 561-567, 2016 | 125 | 2016 |
| Drug interactions: a review of the unseen danger of experimental COVID-19 therapies D Hodge, F Marra, C Marzolini, A Boyle, S Gibbons, M Siccardi, D Burger, ... Journal of Antimicrobial Chemotherapy 75 (12), 3417-3424, 2020 | 50 | 2020 |
| Prescribing nirmatrelvir–ritonavir: how to recognize and manage drug–drug interactions C Marzolini, DR Kuritzkes, F Marra, A Boyle, S Gibbons, C Flexner, ... Annals of internal medicine 175 (5), 744-746, 2022 | 47 | 2022 |
| Recommendations for dosing of repurposed COVID-19 medications in patients with renal and hepatic impairment F Marra, EJ Smolders, O El-Sherif, A Boyle, K Davidson, AJ Sommerville, ... Drugs in R&D 21, 9-27, 2021 | 46 | 2021 |
| COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions D Back, C Marzolini, C Hodge, F Marra, A Boyle, S Gibbons, D Burger, ... British journal of clinical pharmacology 87 (1), 212-213, 2021 | 32 | 2021 |
| Real-world clinical practice use of 8-week glecaprevir/pibrentasvir in treatment-naïve patients with compensated cirrhosis P Lampertico, S Mauss, M Persico, ST Barclay, S Marx, K Lohmann, ... Advances in Therapy 37 (9), 4033-4042, 2020 | 28 | 2020 |
| Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis D Back, P Belperio, M Bondin, F Negro, AH Talal, C Park, ZZ Zhang, ... Journal of viral hepatitis 26 (8), 951-960, 2019 | 23 | 2019 |
| Frequency of potential drug–drug interactions in the changing field of HCV therapy B Schulte, M Wübbolding, F Marra, K Port, MP Manns, D Back, ... Open Forum Infectious Diseases 7 (2), ofaa040, 2020 | 21 | 2020 |
| Real‐world safety and effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in hepatitis C virus genotype 1‐and 4‐infected patients with diverse comorbidities … P Ferenci, S Bourgeois, P Buggisch, S Norris, M Curescu, D Larrey, ... Journal of viral hepatitis 26 (6), 685-696, 2019 | 21 | 2019 |
| Fluvoxamine for the treatment of COVID-19 C Marzolini, F Marra, A Boyle, S Khoo, DJ Back The Lancet Global Health 10 (3), e331, 2022 | 12 | 2022 |
| Real-world outcomes in historically underserved patients with chronic hepatitis C infection treated with glecaprevir/pibrentasvir A Aghemo, Y Horsmans, S Bourgeois, M Bondin, M Gschwantler, H Hofer, ... Infectious diseases and therapy 10 (4), 2203-2222, 2021 | 12 | 2021 |
| Partial directly observed therapy with ombitasvir/paritaprevir based regimens allows for successful treatment of patients on daily supervised methadone A Boyle, F Marra, R Fox, J Morris, C Fleming, E Reilly, M Heydtmann, ... Journal of hepatology 1 (66), S282, 2017 | 11 | 2017 |
| The collaborative care model: realizing healthcare values and increasing responsiveness in the pharmacy workforce P Forsyth, A Radley, GF Rushworth, F Marra, S Roberts, R O'Hare, ... Research in social and administrative pharmacy 19 (1), 110-122, 2023 | 9 | 2023 |
| Ritonavir and COVID-19: pragmatic guidance is important L Waters, F Marra, A Pozniak, J Cockburn, M Boffito The Lancet 399 (10334), 1464-1465, 2022 | 9 | 2022 |
| Corrigendum to ‘EASL recommendations on treatment of hepatitis C: Final update of the series’[J Hepatol 73 (2020) 1170–1218] European Association For The Study Of The Liver Journal of Hepatology 78 (2), 452, 2023 | 7 | 2023 |
| Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis A Boyle, F Marra, E Peters, S Datta, T Ritchie, M Priest, M Heydtmann, ... Journal of Viral Hepatitis 27 (4), 371-375, 2020 | 5 | 2020 |
| weeks sofosbuvir/velpatasvir in genotype 3 patients with significant fibrosis: Highly effective amongst an OST cohort A Boyle, F Marra, E Peters, M Heydtmann, H Cairns, S Datta, S Barclay J Hepatol 68, S20, 2018 | 4 | 2018 |
